Literature DB >> 12195140

Postictal asystole during ECT.

Shyam K Bhat1, Daniel Acosta, Conrad M Swartz.   

Abstract

BACKGROUND: Asystole is an uncommon but potentially fatal complication of electroconvulsive therapy (ECT). Several risks for poststimulus asystole have been described, but risks for asystole at other times have not.
METHOD: Two instances of ECT postictal asystole in healthy adult males are reported. Features in common are identified.
RESULTS: features shared differ from risk factors for poststimulus asystole. In common were adult but not geriatric age, male sex, good physical and cardiac health, mesomorphic habitus, anticholinergic pretreatment, vigorous ECT seizure, and low resting heart rate. Both patients showed postictal bradyarrhythmia at the previous ECT.
CONCLUSIONS: Postictal asystole has apparent similarities to postexertional asystole in athletes. The combination of higher pretreatment doses of an atropinic agent, a sympatholytic agent, and close monitoring of postictal cardiac rhythm should be considered with patients similar to ours, especially after occurrence of postictal bradyarrhythmia.

Entities:  

Mesh:

Year:  2002        PMID: 12195140     DOI: 10.1097/00124509-200206000-00008

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  3 in total

1.  Premedication with dexmedetomidine for prevention of hyperdynamic response after electroconvulsive therapy: a cross-over, randomized controlled trial.

Authors:  Pattika Subsoontorn; Varinee Lekprasert; Punjaporn Waleeprakhon; Pichai Ittasakul; Atchaporn Laopuangsak; Suwimon Limpoon
Journal:  BMC Psychiatry       Date:  2021-08-17       Impact factor: 3.630

2.  Use of Succinylcholine by Anaesthetists in Turkey: A National Survey.

Authors:  Dilek Ömür; Hasan Ali Kiraz; Hasan Şahin; Hüseyin Toman; Berna Uyan; Serpil Ekin; Volkan Hancı
Journal:  Turk J Anaesthesiol Reanim       Date:  2015-08-21

3.  Heart rate changes during electroconvulsive therapy.

Authors:  Josef Nagler
Journal:  Ann Gen Psychiatry       Date:  2013-06-13       Impact factor: 3.455

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.